Alphamab Oncology grants restricted shares to directors and an employee

Alphamab Oncology has announced the grant of 1,990,176 restricted award shares to three eligible participants, including chairman and executive director Dr. Xu Ting, executive director Ms. Liu Yang, and one employee, effective October 24, 2025. Each of the "award directors" received 970,088 shares, while the "award employee" was granted 50,000 shares. The award shares were granted at a purchase price of Nil, with the closing price of shares on the grant date at HK$11.84 per share, and a consideration of RMB1.00 for the award shares.

The award shares for the directors will vest in batches over more than 12 months, aligning with the company's remuneration policy to recognize contributions and judgments to the board. The employee's shares will vest in batches over 48 months, with 10,000 shares vesting annually from October 24, 2026, to October 24, 2028, and the remaining 20,000 shares vesting on October 24, 2029.

The scheme aims to recognize grantee contributions, motivate and retain talent, and align interests among shareholders, the company, and grantees. Performance targets are in place for some awards, with unachieved targets leading to lapsed shares. Following this grant, 94,366,279 shares remain available for future grants under the scheme mandate limit.